11
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A global view of hypertensive disorders and diabetes mellitus during pregnancy

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two important maternal cardiometabolic disorders (CMDs), hypertensive disorders in pregnancy (HDP) (including pre-eclampsia) and gestational diabetes mellitus (GDM), result in a large disease burden for pregnant individuals worldwide. A global consensus has not been reached about the diagnostic criteria for HDP and GDM, making it challenging to assess differences in their disease burden between countries and areas. However, both diseases show an unevenly distributed disease burden for regions with a low income or middle income, or low-income and middle-income countries (LMICs), or regions with lower sociodemographic and human development indexes. In addition to many common clinical, demographic and behavioural risk factors, the development and clinical consequences of maternal CMDs are substantially influenced by the social determinants of health, such as systemic marginalization. Although progress has been occurring in the early screening and management of HDP and GDM, the accuracy and long-term effects of such screening and management programmes are still under investigation. In addition to pharmacological therapies and lifestyle modifications at the individual level, a multilevel approach in conjunction with multisector partnership should be adopted to tackle the public health issues and health inequity resulting from maternal CMDs. The current COVID-19 pandemic has disrupted health service delivery, with women with maternal CMDs being particularly vulnerable to this public health crisis.

          Abstract

          Two maternal cardiometabolic disorders, hypertensive disorders in pregnancy (HDP) and gestational diabetes mellitus (GDM), affect many pregnant individuals worldwide. This Review discusses the global disease burden and risk factors for HDP and GDM and discusses public health interventions that might help reduce the associated mortality and morbidity.

          Key points

          • Hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM) are common cardiometabolic complications of pregnancy.

          • HDP and GDM show an unevenly distributed disease burden (in terms of prevalence, disability-adjusted life years and/or maternal deaths) in low-income and middle-income countries and/or regions with low sociodemographic and human development indexes.

          • In addition to common clinical, demographic and behavioural risk factors, the development and clinical consequences of HDP and GDM are substantially influenced by the socioeconomic determinants of health.

          • Besides prevention and treatment at the individual level, strategies should also be made at different levels and in conjunction with multisector partnerships to improve societal and community conditions to prevent and/or manage HDP and GDM.

          Related collections

          Most cited references268

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

          Summary Background In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and collectively exhaustive list of diseases and injuries. Methods GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories. Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries, health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence, prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. Findings Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group. Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough (ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain (fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries. In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. Interpretation As disability becomes an increasingly large component of disease burden and a larger component of health expenditure, greater research and development investment is needed to identify new, more effective intervention strategies. With a rapidly ageing global population, the demands on health services to deal with disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of universal and more geographically specific influences on health reinforces the need for regular reporting on population health in detail and by underlying cause to help decision makers to identify success stories of disease control to emulate, as well as opportunities to improve. Funding Bill & Melinda Gates Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

            In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) emerged in China and has spread globally, creating a pandemic. Information about the clinical characteristics of infected patients who require intensive care is limited.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

              Coronavirus disease (COVID-19) is caused by SARS-COV2 and represents the causative agent of a potentially fatal disease that is of great global public health concern. Based on the large number of infected people that were exposed to the wet animal market in Wuhan City, China, it is suggested that this is likely the zoonotic origin of COVID-19. Person-to-person transmission of COVID-19 infection led to the isolation of patients that were subsequently administered a variety of treatments. Extensive measures to reduce person-to-person transmission of COVID-19 have been implemented to control the current outbreak. Special attention and efforts to protect or reduce transmission should be applied in susceptible populations including children, health care providers, and elderly people. In this review, we highlights the symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease.
                Bookmark

                Author and article information

                Contributors
                zulfiqar.bhutta@sickkids.ca
                Journal
                Nat Rev Endocrinol
                Nat Rev Endocrinol
                Nature Reviews. Endocrinology
                Nature Publishing Group UK (London )
                1759-5029
                1759-5037
                15 September 2022
                : 1-16
                Affiliations
                [1 ]GRID grid.42327.30, ISNI 0000 0004 0473 9646, Centre for Global Child Health, , The Hospital for Sick Children, ; Toronto, Canada
                [2 ]GRID grid.12527.33, ISNI 0000 0001 0662 3178, Vanke School of Public Health, , Tsinghua University, ; Beijing, China
                [3 ]GRID grid.13097.3c, ISNI 0000 0001 2322 6764, Department of Women and Children’s Health, School of Life Course Sciences, , King’s College London, ; London, UK
                [4 ]GRID grid.29980.3a, ISNI 0000 0004 1936 7830, Department of Obstetrics and Gynecology, Wellington School of Medicine, , University of Otago, ; Wellington, New Zealand
                [5 ]GRID grid.449380.2, ISNI 0000 0001 0823 7860, National University of Samoa, ; Apia, Samoa
                [6 ]GRID grid.7147.5, ISNI 0000 0001 0633 6224, Center of Excellence in Women and Child Health, , the Aga Khan University, ; Karachi, Pakistan
                [7 ]GRID grid.7147.5, ISNI 0000 0001 0633 6224, Institute for Global Health & Development, , the Aga Khan University, ; Karachi, Pakistan
                Author information
                http://orcid.org/0000-0003-4136-3070
                http://orcid.org/0000-0002-7581-8275
                Article
                734
                10.1038/s41574-022-00734-y
                9483536
                36109676
                441813da-872e-461e-9c17-acd959cf25a4
                © Springer Nature Limited 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 28 July 2022
                Categories
                Review Article

                risk factors,public health
                risk factors, public health

                Comments

                Comment on this article